Cogent Biosciences (COGT) stock is in focus after the FDA agreed to accept its New Drug Application for bezuclastinib plus sunitinib in previously treated GIST patients under the Real Time Oncology Review program.

That FDA news drops into a backdrop where the share price has a 90 day share price return of 168.69% and a very large 1 year total shareholder return, so recent momentum looks strong rather than fading.

If this kind of biotech move has your attention, it could be a good moment to see what else is on the radar through healthcare stocks.

With the stock up sharply over the past year and trading at $39.90 versus an average analyst target of $50.25, the key question is whether Cogent Biosciences is still mispriced or if markets already reflect expectations for the company.

Price to Book of 31.2x: Is it justified?

With Cogent Biosciences closing at US$39.90, the stock is trading on a P/B of 31.2x, which screens as very expensive relative to both its biotech peers and the broader US Biotechs industry.

P/B compares the market value of the company to its accounting book value, so a 31.2x reading means investors are paying more than thirty times the net assets on the balance sheet. For a pre revenue, loss making biotech with heavy R&D spend and no meaningful sales yet, a high P/B often reflects market expectations around the future value of the pipeline rather than current fundamentals.

Relative to the US Biotechs industry average P/B of 2.6x and a peer group average of 6.4x, Cogent Biosciences is priced at a substantial premium. That gap suggests the market is placing a much higher value on its drug candidates and future cash flow potential compared with typical sector names, rather than aligning with current balance sheet strength or earnings.

Result: Price to book of 31.2x (OVERVALUED)

However, you still have to weigh clinical and regulatory risk around bezuclastinib, as well as the company’s US$294.372 million net loss and lack of current revenue.

Build Your Own Cogent Biosciences Narrative

If you see the numbers differently or prefer to lean on your own work, you can pull the data together and craft a personal thesis in minutes, starting with Do it your way.

A great starting point for your Cogent Biosciences research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Cogent Biosciences is on your watchlist, do not stop there. Use this moment to widen your search and pressure test your next moves with data.

• Spot potential value setups by scanning these 872 undervalued stocks based on cash flows that align with discounted cash flow metrics and might complement what you already hold.
• Tap into growth themes by checking out these 24 AI penny stocks that are tied to artificial intelligence and related technologies across different parts of the market.
• Add more income focused names to your watchlist by reviewing these 13 dividend stocks with yields > 3% with yields above 3% that could balance higher risk positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.